Cresco Labs Stock Price, News & Analysis

Cresco Labs (OTCQX:CRLBF) reported solid Q2 2025 financial results with revenue of $164 million and Adjusted EBITDA of $41 million, maintaining a 25% EBITDA margin. The company generated $9 million in operating cash flow and achieved a gross margin of 50.6%.

A significant milestone includes securing a commitment letter for a new $325 million term loan to refinance existing debt, strengthening the company's balance sheet and financial flexibility. The quarter saw a net loss of $14 million, which includes $9 million in non-cash impairment charges related to California assets.

The company maintained its #1 market share position in multiple billion-dollar markets while positioning itself for strategic M&A opportunities in the consolidating cannabis industry.

Cresco Labs (OTCQX: CRLBF) has secured commitments to refinance its senior secured credit facility with a new $325 million term loan. The new facility, maturing in 5 years, will replace the existing $360 million credit facility and carries a 12.5% annual interest rate.

The refinancing includes provisions allowing prepayment of up to $125 million at a reduced premium. This strategic move comes amid constrained capital access in the U.S. cannabis sector, with approximately $2 billion in industry debt maturing in the next 18 months. The transaction is expected to close around August 13, 2025.

Cresco Labs (OTCQX:CRLBF) has announced plans to divest its California operations as part of a strategic restructuring initiative. The company will sell its cultivation, manufacturing, and select distribution operations in California while retaining ownership of its premium FloraCal® brand.

The decision comes as Cresco Labs aims to strengthen its balance sheet and increase cash flow by focusing on markets with higher margins and better growth potential. CEO Charlie Bachtell cited structural challenges in California's cannabis market, including fragmented retail, price compression, and illicit market competition, as key factors making sustainable profitability difficult to achieve.

The transaction is expected to close within the next several quarters, subject to regulatory approvals and customary closing conditions.

Cresco Labs (OTCQX:CRLBF), a leading branded cannabis products company and operator of Sunnyside dispensaries, has scheduled its Second Quarter 2025 earnings release for August 7, 2025, before market opening.

The company will host a conference call and webcast at 8:30 am ET to discuss financial results and business highlights. Investors can access the call through US toll-free (1-833-470-1428) or US local (1-404-975-4839) numbers using access code 158138. The webcast recording will be available for one year on Cresco's investor relations website.

Cresco Labs announced a change in its independent auditor from Marcum LLP to Baker Tilly US, LLP, effective June 12, 2025. The transition follows a comprehensive three-month selection process and received approval from both the audit committee and board of directors. Baker Tilly will commence its engagement with the review of Cresco's Q2 2025 financial statements. CFO Sharon Schuler expressed confidence in Baker Tilly's expertise and their future collaboration. Notably, there were no modified opinions in Marcum's previous audit reports, and no reportable events were identified during their tenure. The change of auditor documentation has been filed on SEDAR+ in accordance with regulatory requirements.

Cresco Labs (CRLBF) reported solid Q1 2025 financial results, highlighted by $166 million in revenue and strong cash generation. The company achieved $30 million in operating cash flow and $25 million in Free Cash Flow, ending the quarter with $162 million in cash - its highest balance in three years. Financial metrics include $79 million in gross profit, adjusted gross margin of 49%, and Adjusted EBITDA of $36 million (22% margin). Despite posting a net loss of $15 million, the company maintained its #1 market share position in multiple billion-dollar markets. Management emphasized their focus on balance sheet strength, strategic capital deployment, and reduced credit risk in wholesale accounts.

Cresco Labs (CRLBF) has announced an updated schedule for its first quarter 2025 earnings release. The company will file its Q1 interim financial statements and MD&A on Friday, May 30, 2025. Following a three-week review period with independent auditors, Cresco confirmed no material changes were found from the preparation made for May 9th.

The earnings conference call and webcast is scheduled for Monday, June 2, 2025, at 8:30 am ET. The webcast recording will be accessible for one year through Cresco Labs' investor relations website.

Cresco Labs (CRLBF) has announced the grand opening of a new Sunnyside dispensary in Chippewa Township, Beaver Falls, Pennsylvania. The dispensary, located at 2634 Darlington Road, is strategically positioned just 1.5 miles northwest of I-376, making it easily accessible to patients from nearby towns including New Brighton, West Mayfield, and New Beaver.

According to CEO Charlie Bachtell, Pennsylvania remains a standout market for Cresco Labs, where the company holds the #1 position in branded market share. The new location demonstrates Cresco's strategy of deepening its presence in core states while leveraging its strong retail presence. The dispensary will operate Sunday through Thursday from 9 a.m. to 6 p.m., and Friday and Saturday from 9 a.m. to 7 p.m.

Cresco Labs (CRLBF) has announced the postponement of its Q1 2025 earnings call, originally scheduled for May 9, 2025. The company needs additional time to complete the review procedures for its first quarter interim financial statements. The cannabis company expects to host the rescheduled earnings call and file its Q1 interim financial statements by the required filing deadline of May 30, 2025. A new earnings call date will be announced once determined.